Acumen Pharma Q3 2026 Conference Call and Webcast - ACUMEN PHARMACEUTICALS INC

Financial Performance:

• Ended Q3 2026 with $79 million in cash and marketable securities, sufficient to fund operations into early 2027.
• Total R&D expenses were $21.1 million, down from prior year levels due to reduced manufacturing, materials, and CRO costs associated with the Altitude AD trial.
• G&A expenses were $4.7 million, remaining flat year-over-year.
• Reported a loss from operations of $25.8 million and a net loss of $24.5 million for the quarter.
• No revenue was generated in the period as the company remains in the clinical development stage.

Guidance and Future Outlook:

• Anticipates announcing top-line Phase II "Altitude AD" results in November 2026.
• A single confirmatory Phase III trial is planned to follow immediately if Phase II results meet success criteria.
• Next-generation Enhanced Brain Delivery (EBD) candidates (ACU301 and ACU401) are on track for an IND filing by mid-2027.
• Long-term roadmap includes evaluating subcutaneous dosing formulations for Phase III and potential early time-point efficacy readouts if the drug demonstrates rapid symptomatic benefit.

Business Segments and Product Lines:

• Sobernitog (Suburnatug): Lead product candidate, a selective anti-A-beta-oligomer IgG2 monoclonal antibody; currently under evaluation in the Phase II Altitude AD trial testing 35 mg/kg and 50 mg/kg IV doses every four weeks.
• Enhanced Brain Delivery (EBD) Program: Two candidates advanced: ACU301 (bispecific antibody) and ACU401 (novel A-beta-selective antibody); ACU401 demonstrated up to 40-fold greater frontal cortex exposure in non-human primates compared to unmodified antibodies.
• Pipeline Strategy: Focusing on the A-beta oligomer hypothesis to target toxic soluble species rather than plaques, with plans to incorporate subcutaneous administration in future Phase III studies based on completed bioavailability data.

Market and Competitive Landscape:

• Positioned Sobernitog as a differentiated therapy targeting soluble oligomers, contrasting with current market standard treatments that focus on plaque clearance (e.g., Denuumab, Lequembe).
• Management views oligomer targeting as potentially effective as a primary therapy or a maintenance/follow-on treatment post-plaque clearance.
• Key opinion leaders (KOLs) express high interest in the unique mechanism, hoping it could shift treatment paradigms from plaque-busting to toxic species neutralization.
• Competitors like Biogen are positioning their plaque-clearing drugs as initial therapies, creating an opportunity for oligomer-selective agents to fill the post-clearance treatment gap.

Risks and Challenges:

• Binary clinical risk: The November Phase II readout is the critical milestone; failure to demonstrate statistically significant efficacy on the iGRIS endpoint could stall the program.
• Safety risks include potential adverse events such as Amyloid-Related Imaging Abnormalities (ARIA), infusion site reactions, and low double-digit ARIA-e rates, which must remain manageable for Phase III progression.
• Dependency on the unproven "oligomer hypothesis" for Alzheimer's disease, as this is the first large-scale test of this mechanism.
• Potential for missing data or patient discontinuation in the primary study, though retention rates have currently exceeded expectations.

Management Commentary and Tone:

• Management expressed high confidence in the study execution, citing rapid enrollment, high operational standards, and a >95% rollover rate into the open-label extension.
• Tone was optimistic regarding the data readout, emphasizing that both tested doses fall within a predicted zone of efficacy with an attractive benefit-to-risk profile.
• Executives highlighted the robustness of the pipeline, noting that the EBD program's preclinical data exceeded expectations regarding brain penetration and selectivity.
• Emphasis was placed on the strategic value of the November results in validating the central scientific thesis and generating value-creating milestones.

Analyst Questions and Answers:

• Biogen/Denuumab Interaction: Confirmed that Sobernitog could logically serve as a maintenance therapy after plaque clearance by other agents, though Phase II primary endpoints remain focused on the initial 18-month treatment period.
• Dose Selection: Clarified that 35 mg/kg and 50 mg/kg doses were selected based on Phase I pharmacodynamics and modeling; the higher dose may show stronger amyloid PET signal effects.
• Success Criteria: Defined Phase II success as a 30% slowing of disease progression on the iGRIS scale after 18 months; safety must show low double-digit ARIA rates consistent across genotypes.
• Rapid Efficacy: Acknowledged the possibility of faster symptomatic benefits due to monomer binding; the study design allows for capturing earlier timepoint data if mechanism warrants.
• KOL Feedback: Reinforced that physicians are seeking alternatives to plaque-busting, viewing oligomer targeting as a potential paradigm shift.
• Patient Retention: Confirmed retention exceeded expectations in the primary study; missing data will be handled via conventional per-protocol analysis.
• Subcutaneous Formulation: Confirmed bioavailability study is complete; plans to incorporate subcutaneous dosing in Phase III, potentially modeling approaches used by competitors like Biogen.

Other Key Points:

• The Altitude AD trial is designed to assess both efficacy (iGRIS, CDR-SOB) and safety (ARIA, adverse events), alongside biomarker changes in CSF and plasma (e.g., p-tau217).
• Open-label extension data will continue to be generated into 2027, with high participation (>95% of eligible patients).
• The EBD program offers strategic optionality with two distinct candidates (ACU301 and ACU401) to diversify development paths.
• Management reiterated commitment to the A-beta oligomer-targeted portfolio as a core value driver for stakeholders.